Highlights
- The FDA accepted the REVTORPYK application for PIK3CA-mutant advanced breast cancer, with a decision date of June 25, 2027.
- Celcuity reported a third quarter 2026 net loss of $73,337 thousand, or $1.33 per share, and no product revenue.
- Cash, cash equivalents and short-term investments were $642.7 million, which the company believes will finance operations through 2029.
- The FDA approved the REVTORPYK NDA on July 14, 2026, and shipments began on September 30, 2026.
Celcuity Inc. (NASDAQ:CELC) shares were trading at USD 57.85 on November 17, 2026, down 4.49%, with a relative Volume at time of 2.06. The commercial-stage biotechnology company received FDA approval of REVTORPYK on July 14, 2026, filed its third quarter 2026 report on November 5, and the FDA accepted its supplemental new drug application with a decision date of June 25, 2027.
Celcuity is a Delaware corporation with principal executive offices in Minneapolis, Minnesota. It develops and commercializes targeted cancer therapies. Its first FDA-approved product is REVTORPYK (gedatolisib), a pan-PI3K and mTORC1/2 inhibitor approved for adult patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy. The company also runs the VIKTORIA-2 Phase 3 breast cancer trial and the CELC-G-201 Phase 1b/2 prostate cancer trial. It has incurred losses in each period since its inception in 2012. Its fiscal year ends December 31.
FDA Accepts Supplemental Application
The FDA accepted Celcuity's supplemental new drug application (sNDA) for REVTORPYK in PIK3CA-mutant advanced breast cancer, with a decision date of June 25, 2027. Celcuity submitted the sNDA on August 26, 2026, based on data from the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial. The company said it intends to submit VIKTORIA-1 data to regulators outside the U.S. later this year or early next year.
Third Quarter 2026 Results
For the quarter ended September 30, 2026, Celcuity reported a net loss of $73,337 thousand, compared with $43,804 thousand a year earlier, and a net loss per share of $1.33, compared with $0.92. It recognized no product revenue, since providers and pharmacies received no product until after September 30, 2026.
Research and development expenses were $37,519 thousand, compared with $30,425 thousand. Selling, general and administrative expenses were $39,800 thousand, compared with $12,424 thousand, which the company attributed mainly to employee-related and commercialization costs. Total operating expenses were $77,319 thousand, compared with $42,849 thousand. For the nine months, the net loss was $205,042 thousand and included a loss on Debt extinguishment of $11,477 thousand.
Balance Sheet, Debt and Cash Flow
At September 30, 2026, cash and cash equivalents were $178,165 thousand and investments were $464,538 thousand. Total liabilities were $800,908 thousand, including convertible notes of $753,958 thousand, and total stockholders' Equity (deficit) was a Deficit of $74,039 thousand. As of October 29, 2026, 49,126,314 shares of common stock were outstanding.
In June 2026, the company issued $575.0 million of 0.250% convertible notes due 2032 for net proceeds of $557.0 million and prepaid its Amended A&R Loan Agreement with a payment of $137.4 million. Net cash used in Operating Activities was $176,717 thousand for the nine months. The company said selling equity or convertible debt securities may result in dilution.
Launch, Pipeline and Outlook
Shipments of REVTORPYK began on September 30, 2026. On the call, management said it expects to provide a flash report on fourth quarter sales in mid-January and does not expect its second Manufacturing site to be approved until the middle of 2027.
Celcuity expects a randomized Phase 2 prostate cancer study to begin in the first half of 2027 and topline data for VIKTORIA-2 Study 1 by the end of 2028 or the first half of 2029, and for Study 2 in 2030. It expects Research and Development and selling, general and administrative expenses to increase, and believes its cash and investments will finance operations through 2029, based on assumptions that may not be accurate.






Please wait processing your request...